Video Summary
Gram-positive, catalase-positive cocci that grow in grape-like clusters and form golden colonies on blood agar.
About 25% of people carry S. aureus on skin or nares; colonization can progress to infection after skin breaks or high bacterial loads.
Coagulase test differentiates S. aureus (coagulase-positive) from other staphylococci.
Causes a spectrum from superficial skin infections (impetigo, abscesses) to deep or systemic disease (osteomyelitis, endocarditis, sepsis).
Produces toxins (TSST-1, PVL, hemolysins, exfoliatin, enterotoxins) that drive specific syndromes like toxic shock and food poisoning.  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​ Â
Catalase differentiates staphylococci (catalase‑positive) from streptococci (catalase‑negative) by bubbling with H2O2. Coagulase distinguishes S. aureus (coagulase‑positive, causes fibrin clotting) from other staphylococci like S. epidermidis (coagulase‑negative).
Roughly 25% of people carry S. aureus on skin sites such as the nostrils, groin, and armpits. Infection occurs when bacterial burden rises or the skin barrier is breached (microfissures, wounds, surgery), allowing invasion.
Beyond superficial skin disease, S. aureus can cause abscesses, pyomyositis, osteomyelitis, septic arthritis, pneumonia, meningitis, infective endocarditis, bacteremia, and sepsis with hypotension and organ hypoperfusion.
Biofilms form on natural and artificial surfaces (catheters, prostheses) creating a protective EPS matrix that impedes antibiotics and immune clearance; cells within can share resistance genes, making infections persistent and hard to eradicate.
MRSA strains carry the mecA gene, which encodes altered penicillin‑binding proteins (PBPs) that reduce binding of beta‑lactam antibiotics, rendering methicillin and related drugs ineffective.
Treatment is guided by susceptibility testing and local antibiograms. MRSA often requires non‑beta‑lactams such as vancomycin, clindamycin, linezolid, daptomycin, or others depending on susceptibility and infection severity.
"Staphylococcus aureus, or staph aureus, is a round-shaped bacterium that grows in clusters resembling grapes."
Staphylococcus aureus is commonly known for its coccal shape and cluster growth, which can be observed under a microscope. The term "aureus" means "golden," referencing the distinctive golden-yellow coloration of its colonies when grown on blood agar plates.
This bacterium is classified as Gram-positive due to its peptidoglycan-rich cell wall, which results in a purple stain during Gram staining protocols.
"Staphylococcus aureus is a non-motile, facultative anaerobe that produces catalase, allowing it to differentiate from other cocci."
As a facultative anaerobe, Staphylococcus aureus can thrive in both aerobic and anaerobic conditions. It does not form spores and is non-motile.
The production of the enzyme catalase differentiates Staphylococcus aureus from other cocci such as streptococci and enterococci, which are catalase-negative. When tested with hydrogen peroxide, catalase-positive bacteria will produce a noticeable foam.
"Staphylococcus aureus can colonize the skin and penetrate through microfissures leading to localized skin infections."
Approximately a quarter of the population carries Staphylococcus aureus as part of their normal skin flora, primarily in mucosal areas such as the nostrils, groin, and armpits.
The penetration of staph aureus through small breaks in the skin, such as cuts or eczema, can lead to infections ranging from localized skin infections, like pimples, to more severe conditions such as cellulitis and abscess formation.
"When Staphylococcus aureus infections go deeper, they can cause conditions like osteomyelitis or septic arthritis."
Infections can manifest as furuncles or carbuncles and may escalate to more severe conditions if left untreated.
If bacteria enter the bloodstream, it can lead to systemic infections, including septic thrombophlebitis and bacteremia, which may result in a severe immune response known as sepsis, characterized by low blood pressure and poor organ perfusion.
"Staphylococcus aureus can create biofilms on medical implants, making infections difficult to eradicate."
The ability to form biofilm, a slimy layer composed of exopolysaccharides that protect the bacteria, makes treatment challenging. Antibiotics often struggle to penetrate these biofilms, and physical removal of the infected surface might be necessary for resolution.
Biofilms can develop on indwelling catheters, prosthetic devices, and other surfaces, and the bacteria within them can communicate and exchange resistance genes, leading to persistent infections.
"Staphylococcus aureus can release several major toxins that contribute to its pathogenicity."
The bacteria secrete various toxins, including TSST-1, which can cause toxic shock syndrome by triggering an overwhelming immune response known as a cytokine storm.
Other toxins such as PVL and hemolysin damage immune cells and red blood cells, respectively, while exfoliatin causes skin conditions like staphylococcal scalded skin syndrome.
The enterotoxin can survive cooking temperatures and may lead to food poisoning if ingested, demonstrating the bacterium's versatile mechanisms of causing disease.
"Staphylococcus aureus has rapidly developed resistance to multiple antibiotics, complicating treatment options."
Early attempts to treat infections with penicillin faced challenges due to the bacteria's ability to adapt and develop resistance.
Penicillins target the enzyme responsible for synthesizing the peptidoglycan layer of the bacterial cell wall, but when resistance develops, treatment becomes significantly more difficult requiring close monitoring and alternative therapies.
"Staphylococcus aureus can’t replicate and create more cell wall, leading to its death."
When Staphylococcus aureus attempts to divide, it faces challenges in forming a new cell wall, ultimately resulting in its death.
Most strains of Staphylococcus aureus today produce beta-lactamases, enzymes that deactivate beta-lactam antibiotics by breaking their beta-lactam ring structure.
To combat this resistance, beta-lactamase inhibitors like clavulanic acid were developed to bind to and inactivate beta-lactamases.
New beta-lactam antibiotics, such as methicillin, have been introduced which are not easily deactivated by these beta-lactamases.
"Some MRSA strains have evolved to carry the mecA gene, giving them resistance to beta-lactam antibiotics."
Unfortunately, certain strains of Staphylococcus aureus have further evolved by expressing a gene known as mecA. This gene encodes for specific penicillin-binding proteins (PBPs) that are unaffected by beta-lactam antibiotics.
As a result, methicillin and older penicillin derivatives cannot effectively bind to these PBPs, rendering them useless against these resistant strains.
These strains are known as Methicillin-resistant Staphylococcus aureus (MRSA) and have become increasingly prevalent worldwide.
"MRSA infections cannot be treated with beta-lactam antibiotics."
There are two major classifications of MRSA: healthcare-associated MRSA (HA-MRSA) and community-associated MRSA (CA-MRSA).
HA-MRSA is typically found in healthcare settings such as hospitals and nursing homes, where there are many chronically ill patients and high usage of antibiotics.
Conversely, CA-MRSA is found in community settings and is attributed to excessive antibiotic use in factory farming and the overprescription of antibiotics.
Both HA-MRSA and CA-MRSA present significant treatment challenges as infections caused by these strains cannot be managed with beta-lactam antibiotics.
"Vancomycin is an alternative but comes with side effects."
When treating MRSA infections, healthcare providers often resort to glycopeptide antibiotics like vancomycin, which is recognized as an alternative treatment.
However, vancomycin is not as effective as desired and introduces problematic side effects.
Alarmingly, some strains of Staphylococcus aureus have developed intermediate resistance to vancomycin, known as "vancomycin-intermediate S. aureus" (VISA), while those with complete resistance are termed "vancomycin-resistant S. aureus" (VRSA).
"The treatment process involves testing bacteria against various antibiotics."
Effectively treating Staphylococcus aureus infections requires testing the bacteria against a range of antibiotics to identify the most effective one.
Hospitals often compile an antibiogram, a document that illustrates the resistance patterns of various bacteria to specific antibiotics.
Common choices for MRSA treatment include clindamycin and vancomycin, but there are alternatives available such as tetracyclines, trimethoprim/sulfamethoxazole, linezolid, tigecycline, daptomycin, and quinupristin-dalfopristin.
"S. aureus is a gram-positive coccus that can become pathogenic."
Staphylococcus aureus is a gram-positive coccus that typically clusters together, and about 25% of the population carries it as part of their normal skin and nasal flora.
If it overgrows or infects damaged skin, S. aureus can lead to diseases through direct colonization or toxin production.
The adaptability of Staphylococcus aureus has allowed it to develop resistance to various antibiotics, with methicillin-resistant strains classified as HA-MRSA or CA-MRSA, while vancomycin-resistant strains are categorized as VISA and VRSA.
